Pioneering Antiviral Conjugates With Cidara's Dr. Jeff Stein
Source: Bioprocess Online
![20_12_BPO_BusBiotech_Social_ep34 20_12_BPO_BusBiotech_Social_ep34](https://vertassets.blob.core.windows.net/image/5257aa5c/5257aa5c-60ef-4f85-867a-34cafa762cac/375_250-20_12_bpo_busbiotech_social_ep34.png)
Cidara Therapeutics President and CEO Dr. Jeff Stein joins the Business of Biotech to discuss his career mission to battle microbial organisms and his company's development of a novel approach to producing immunotherapeutic antivirals that couple potent antivirals to a human antibody fragment. We discuss the company's manufacturing approach, which Dr. Stein anticipates yielding a low-cost alternative to standards of care in multiple antiviral indications.
access the Podcast!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more